For its first fiscal quarter (ending March 31), Edwards Lifesciences Corp (NYSE: EW) has reported E.P.S. of $0.58 compared to $0.56 a year ago. E.P.S. were $2.33 for the latest four quarters through March 31 versus $2.41 for the same period a year ago.
Recent Price Action
On 4/25/24, Edwards Lifesciences Corp (NYSE: EW) stock declined slightly by -0.7%, closing at $88.01. Moreover, above average trading volume at 122% of normal accompanied the decline. The stock has risen 0.9% during the last week and has been strong relative to the market over the last nine months.
Current PriceTarget Research Rating
Reflecting future returns on capital that are forecasted to exceed the cost of capital, EW is expected to continue to be a major Value Builder.
Edwards Lifesciences has a current Value Trend Rating of D (Negative). The Value Trend Rating reflects very contradictory signals from PTR’s two proprietary measures of a stock’s attractiveness. Edwards Lifesciences has a poor Appreciation Score of 16 but a good Power Rating of 70, producing the Negative Value Trend Rating.
Rating Review
In light of this new information we are reviewing our current Overall Rating of D. This review will be completed in the next several days.
Be the first to comment